Product
Risankizumab
Aliases
ABBV-066, BI 655066, placebo for risankizumab, Placebo for Risankizumab (3 other aliases)
28 clinical trials
12 indications
Indication
PsoriasisIndication
Psoriatic ArthritisIndication
Crohn's DiseaseIndication
RisankizumabIndication
Palmoplantar PustulosisIndication
Ulcerative ColitisIndication
Crohn's diseaseIndication
Healthy Control ParticipantsIndication
Psoriasis VulgarisIndication
Juvenile Psoriatic ArthritisIndication
COVID-19Indication
Inflammatory Bowel DiseaseClinical trial
Risankizumab Pregnancy Exposure Registry: a Prospective Observational Study on the Safety of Risankizumab Exposure in Pregnant Women and Their OffspringStatus: Recruiting, Estimated PCD: 2033-01-01
Clinical trial
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor Blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyStatus: Not yet recruiting, Estimated PCD: 2025-03-24
Clinical trial
A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisStatus: Active (not recruiting), Estimated PCD: 2024-02-12
Clinical trial
A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseStatus: Completed, Estimated PCD: 2022-10-14
Clinical trial
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult Japanese Subjects With Moderate to Severe Palmoplantar PustulosisStatus: Completed, Estimated PCD: 2022-11-21
Clinical trial
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1)Status: , Estimated PCD: 2029-11-15
Clinical trial
A Phase 1 Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab 150mg/mL Formulation in the 180 mg Prefilled Syringe Relative to 90mg/mL Formulation in the 90 mg Prefilled SyringeStatus: Completed, Estimated PCD: 2023-04-20
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's DiseaseStatus: Active (not recruiting), Estimated PCD: 2026-06-09
Clinical trial
Post-Marketing Real World Safety Study of Risankizumab in the United StatesStatus: Withdrawn, Estimated PCD: 2022-03-10
Clinical trial
IMMprint: A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study Evaluating Safety and Efficacy of Risankizumab Compared to Placebo in Adult Subjects With Moderate to Severe Plaque Psoriasis With Palmoplantar (Non-Pustular) Involvement (PPPsO)Status: Completed, Estimated PCD: 2023-04-20
Clinical trial
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2)Status: Active (not recruiting), Estimated PCD: 2020-06-22
Clinical trial
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)Status: Active (not recruiting), Estimated PCD: 2020-10-08
Clinical trial
A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF TherapyStatus: Active (not recruiting), Estimated PCD: 2028-02-11
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2028-09-25
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative ColitisStatus: Completed, Estimated PCD: 2022-11-09
Clinical trial
A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Have a Suboptimal Response to Secukinumab or Ixekizumab and Are Switched to RisankizumabStatus: Completed, Estimated PCD: 2022-01-17
Clinical trial
PATHFINDER: A Pragmatic, Active-comparator, Parallel-group, Randomized Trial to Evaluate the Optimal First-line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2027-07-30
Clinical trial
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects With Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp PsoriasisStatus: Recruiting, Estimated PCD: 2024-09-27
Clinical trial
A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab in Vials Manufactured by Two Different ProcessesStatus: Completed, Estimated PCD: 2024-05-06
Clinical trial
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2026-03-27
Clinical trial
Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio StudyStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2029-04-28
Clinical trial
Open-label, Randomized, Assessor-blinded, Efficacy, Safety, Tolerability, and Pharmacokinetics Study of Subcutaneous Risankizumab With an Adalimumab Reference Arm in Children With Active Juvenile Psoriatic ArthritisStatus: Recruiting, Estimated PCD: 2026-09-13
Clinical trial
A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized AdultsStatus: Completed, Estimated PCD: 2021-09-13
Clinical trial
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyStatus: Completed, Estimated PCD: 2023-04-20
Clinical trial
A Phase 4, Open-Label, Milk-Only Lactation Study to Assess Concentration of Risankizumab in Breast Milk of Lactating Women With Inflammatory Bowel Disease Who Are Receiving Risankizumab TherapeuticallyStatus: Recruiting, Estimated PCD: 2025-01-20
Clinical trial
Risankizumab in Children With Crohn's Disease (RisaKids): A Multi-center PORTO Group Prospective StudyStatus: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 1, Open-label Study to Assess PK Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2025-04-29